Cargando…
Health‐related quality of life in patients with heart failure eligible for treatment with sacubitril–valsartan
AIM: To describe and compare self‐reported health‐related quality of life between younger and older patients with severe heart failure eligible for treatment with sacubitril–valsartan and to explore the association between health‐related quality of life and age, NYHA classification, systolic blood p...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024611/ https://www.ncbi.nlm.nih.gov/pubmed/32089852 http://dx.doi.org/10.1002/nop2.420 |
_version_ | 1783498435834413056 |
---|---|
author | Holmlund, Lena Brännström, Margareta Lindmark, Krister Sandberg, Camilla Hellström Ängerud, Karin |
author_facet | Holmlund, Lena Brännström, Margareta Lindmark, Krister Sandberg, Camilla Hellström Ängerud, Karin |
author_sort | Holmlund, Lena |
collection | PubMed |
description | AIM: To describe and compare self‐reported health‐related quality of life between younger and older patients with severe heart failure eligible for treatment with sacubitril–valsartan and to explore the association between health‐related quality of life and age, NYHA classification, systolic blood pressure and NT‐proBNP level. DESIGN: Cross‐sectional study. METHODS: A total of 59 patients, eligible for treatment with sacubitril–valsartan were consecutively included and divided into a younger (≤75 years) and older group (>75 years). Health‐related quality of life was assessed using the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5‐dimensions. Data were collected between June 2016 and January 2018. The STROBE checklist was used. RESULTS: There were no differences in overall health‐related quality of life between the age groups. The older patients reported lower scores in two domains measured with the Kansas City Cardiomyopathy Questionnaire, namely self‐efficacy (67.0 SD 22.1 vs. 78.8 SD 19.7) and physical limitation (75.6 SD 19.0 vs. 86.3 SD 14.4). Higher NYHA class was independently associated with lower Kansas City Cardiomyopathy Questionnaire Overall Summary Score. |
format | Online Article Text |
id | pubmed-7024611 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70246112020-02-21 Health‐related quality of life in patients with heart failure eligible for treatment with sacubitril–valsartan Holmlund, Lena Brännström, Margareta Lindmark, Krister Sandberg, Camilla Hellström Ängerud, Karin Nurs Open Research Articles AIM: To describe and compare self‐reported health‐related quality of life between younger and older patients with severe heart failure eligible for treatment with sacubitril–valsartan and to explore the association between health‐related quality of life and age, NYHA classification, systolic blood pressure and NT‐proBNP level. DESIGN: Cross‐sectional study. METHODS: A total of 59 patients, eligible for treatment with sacubitril–valsartan were consecutively included and divided into a younger (≤75 years) and older group (>75 years). Health‐related quality of life was assessed using the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5‐dimensions. Data were collected between June 2016 and January 2018. The STROBE checklist was used. RESULTS: There were no differences in overall health‐related quality of life between the age groups. The older patients reported lower scores in two domains measured with the Kansas City Cardiomyopathy Questionnaire, namely self‐efficacy (67.0 SD 22.1 vs. 78.8 SD 19.7) and physical limitation (75.6 SD 19.0 vs. 86.3 SD 14.4). Higher NYHA class was independently associated with lower Kansas City Cardiomyopathy Questionnaire Overall Summary Score. John Wiley and Sons Inc. 2019-11-19 /pmc/articles/PMC7024611/ /pubmed/32089852 http://dx.doi.org/10.1002/nop2.420 Text en © 2019 The Authors. Nursing Open published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Holmlund, Lena Brännström, Margareta Lindmark, Krister Sandberg, Camilla Hellström Ängerud, Karin Health‐related quality of life in patients with heart failure eligible for treatment with sacubitril–valsartan |
title | Health‐related quality of life in patients with heart failure eligible for treatment with sacubitril–valsartan |
title_full | Health‐related quality of life in patients with heart failure eligible for treatment with sacubitril–valsartan |
title_fullStr | Health‐related quality of life in patients with heart failure eligible for treatment with sacubitril–valsartan |
title_full_unstemmed | Health‐related quality of life in patients with heart failure eligible for treatment with sacubitril–valsartan |
title_short | Health‐related quality of life in patients with heart failure eligible for treatment with sacubitril–valsartan |
title_sort | health‐related quality of life in patients with heart failure eligible for treatment with sacubitril–valsartan |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024611/ https://www.ncbi.nlm.nih.gov/pubmed/32089852 http://dx.doi.org/10.1002/nop2.420 |
work_keys_str_mv | AT holmlundlena healthrelatedqualityoflifeinpatientswithheartfailureeligiblefortreatmentwithsacubitrilvalsartan AT brannstrommargareta healthrelatedqualityoflifeinpatientswithheartfailureeligiblefortreatmentwithsacubitrilvalsartan AT lindmarkkrister healthrelatedqualityoflifeinpatientswithheartfailureeligiblefortreatmentwithsacubitrilvalsartan AT sandbergcamilla healthrelatedqualityoflifeinpatientswithheartfailureeligiblefortreatmentwithsacubitrilvalsartan AT hellstromangerudkarin healthrelatedqualityoflifeinpatientswithheartfailureeligiblefortreatmentwithsacubitrilvalsartan |